STOCKHOLM, March 5, 2026 /PRNewswire/ -- SciBase Holding AB ("SciBase") (STO: SCIB), a leading developer of AI-based diagnostic solutions for skin disorders, announced that Stephen D. Hess, MD, PhD, FAAD, has published a clinical article highlighting his real-world experience integrating Nevisense into routine melanoma detection. The article was published in The Dermatologist, a leading U.S. clinical dermatology journal.

In the publication, Dr. Hess outlines how Nevisense provides objective data to complement visual examination and dermoscopy when evaluating atypical pigmented lesions, and that Nevisense adds objective risk stratification in cases that are clinically challenging.

"In everyday practice, many pigmented lesions fall into a diagnostic gray zone," said Dr. Hess. "Nevisense adds objective, real-time information beneath the skin's surface, enhancing clinical judgment and supporting more accurate biopsy decisions."

"As melanoma incidence continues to rise, clinicians need reliable technology that provides actionable data," said Pia Renaudin, CEO of SciBase. "Dr. Hess's publication in The Dermatologist highlights the growing importance of objective technologies like Nevisense in advancing melanoma detection and improving patient outcomes."

The article can be found here: https://www.hmpgloballearningnetwork.com/site/thederm/practice-advances/precision-under-surface-electrical-impedance-spectroscopy-pigmented

For further information, please contact:
Pia Renaudin, CEO
Phone: +46 73 206 98 02
Email: pia.renaudin@scibase.com

Certified Advisor (CA):
DNB Carnegie Investment Bank AB (publ)
Tel: +46 8 588 68 570
Email: certifiedadviser@carnegie.se

About SciBase and Nevisense

SciBase is a global medical technology company, specializing in early detection and prevention in dermatology. SciBase develops and commercializes Nevisense, a unique point-of-care platform that combines AI (artificial intelligence) and advanced EIS technology to enhance diagnostic accuracy, ensuring proactive skin health management.

Our commitment is to minimize patient suffering, allowing clinicians to improve and save lives through timely detection and intervention and reduce healthcare costs.

Built on more than 20 years of research at Karolinska Institute in Stockholm, Sweden, SciBase is a leader in dermatological advancements.

The company has been on the Nasdaq First North Growth Market exchange since June 2, 2015 and the company's Certified Adviser is DNB Carnegie Investment Bank AB (publ). Learn more at www.scibase.com . For press releases and financial reports visit: http://investors.scibase.se/en/pressreleases

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/scibase/r/new-publication--us-clinicians--real-world-nevisense-experience-improves-melanoma-detection,c4316723

The following files are available for download:


 
 https://mb.cision.com/Main/12371/4316723/3964809.pdf PR Dr. Hess

View original content:https://www.prnewswire.co.uk/news-releases/new-publication-us-clinicians-real-world-nevisense-experience-improves-melanoma-detection-302705056.html

Tags

More Like This

New review article highlights Nevisense effectiveness in identifying malignant skin lesions

SciBase reaches milestone with over 300,000 patients tested with Nevisense

New German study shows Nevisense significantly improves dermatologists clinical decisions

New US Consensus Report supports Nevisense

The Mayo Clinic, the leading US hospital, will test Nevisense in Pilot

New study shows significant improved clinical accuracy with Nevisense for both US and German dermatologists

SciBase: A new important customer in the US, Palm Beach Dermatology Group, has placed an initial order for 6 Nevisense.

SciBase Launches Nevisense Pilot at Leading University in Southeast Florida